Drug Type Monoclonal antibody |
Synonyms |
Target |
Mechanism KLRG1 inhibitors(killer cell lectin like receptor G1 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization Abcuro, Inc.Startup |
Active Organization Abcuro, Inc.Startup |
Inactive Organization- |
Drug Highest PhasePhase 2/3 |
First Approval Date- |
RegulationOrphan Drug (EU) |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Myositis, Inclusion Body | Phase 3 | FR | Abcuro, Inc.Startup | 28 Feb 2023 |
Myositis, Inclusion Body | Phase 3 | AU | Abcuro, Inc.Startup | 28 Feb 2023 |
Myositis, Inclusion Body | Phase 3 | BE | Abcuro, Inc.Startup | 28 Feb 2023 |
Myositis, Inclusion Body | Phase 3 | DE | Abcuro, Inc.Startup | 28 Feb 2023 |
Myositis, Inclusion Body | Phase 3 | GB | Abcuro, Inc.Startup | 28 Feb 2023 |
Myositis, Inclusion Body | Phase 3 | CA | Abcuro, Inc.Startup | 28 Feb 2023 |
Myositis, Inclusion Body | Phase 3 | US | Abcuro, Inc.Startup | 28 Feb 2023 |
Large Granular Lymphocytic Leukemia | Phase 2 | US | Abcuro, Inc.Startup | 08 Sep 2022 |
Phase 1 | Myositis, Inclusion Body large granular lymphocytes (LGLs) | 6 | (lnmufhzhuh) = One unrelated serious AE of fall with muscle tear in a C1 participant with a prior history of falls occurred phckdewhxc (ikxlkzhrjl ) | - | 01 Jun 2022 | ||